Overview: ANCA Myeloperoxidase TestIntroduction: The ANCA Myeloperoxidase Test detects antibodies to myeloperoxidase to diagnose autoimmune vasculitis, which may cause joint pain, fatigue, or organ damage. Following 2023 ACR guidelines, it uses an immunoassay for high sensitivity, aiding in autoimmune screening. This test is critical for guiding treatment, monitoring disease activity, and improving outcomes in immunology for patients with suspected vasculitis.
Other Names: ANCA-MPO Assay, Anti-Myeloperoxidase Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: ANCA testing began in the 1980s with immunofluorescence. Specific myeloperoxidase assays emerged in the 1990s, and by the 2000s, immunoassays improved specificity for vasculitis diagnosis.
Purpose: Diagnoses autoimmune vasculitis, guides treatment, and monitors disease activity in patients with joint pain, fatigue, or organ damage.
Test Parameters: 1. Anti Myeloperoxidase Antibodies
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like joint pain or fatigue, and list medications like immunosuppressants.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document vasculitis symptoms, autoimmune disease history, or family history of autoimmune disorders. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for immunosuppressive therapy.
Procedural Considerations: Uses an immunoassay to measure anti-myeloperoxidase antibodies. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Immunosuppressants may suppress antibody levels, causing false negatives. Hemolysis or improper storage can degrade samples.
Clinical Significance: Positive results confirm vasculitis, prompting immunosuppressive therapy. Negative results may require ANCA-PR3 testing for confirmation.
Specialist Consultation: Consult a rheumatologist for result interpretation. A nephrologist referral is advised for kidney involvement.
Additional Supporting Tests: ANCA-PR3 test, ESR, or renal function tests to confirm vasculitis or assess organ damage.
Test Limitations: False negatives may occur with immunosuppressive therapy. Cross-reactivity with other autoantibodies requires clinical correlation.
References: ACR Vasculitis Guidelines, 2023; Arthritis and Rheumatology, Kallenberg CG, 2022.
